Baylor College of Medicine Cancer Center-Cancer Center Support Grant

贝勒医学院邓肯综合癌症中心丹·L 总体--项目摘要 这是丹·L邓肯综合癌症中心的第三次CCSG竞争续签申请 (DLDCCC)在德克萨斯州休斯顿的贝勒医学院(BCM)。休斯顿是世界上第四大城市 美国人口非常多样化，哈里斯县是世界上人口增长最快的县之一 国家。DLDCCC集水区已经从哈里斯县的核心扩大到包括8个 包括休斯敦大都会统计区(MSA)的周边县，代表着 人口多样化，超过700万人(这一人口超过35个州)。这个 DLDCCC是一个矩阵中心，BCM是主要合作伙伴，有4家医院附属公司、德克萨斯儿童医院、 DeBakey退伍军人事务医疗中心、Ben Taub医院和新的贝勒·圣卢克医疗中心 作为正式的附属公司。DLDCCC于2007年获得NCI称号，2014年获得综合称号 并通过我们的评估和规划过程以及我们的选管会和内部 自那以后，我们在加强我们的科学计划方面取得了重大进展。53例新癌症 DLDCCC目前有192名研究成员，78名临床成员和 18名附属会员。我们与癌症相关的同行评议研究资金现在超过1.69亿美元， 超过4900万美元(3400万美元)直接来自NCI。几项重要的科学成就 对我们的集水区和全球都产生了影响。DLDCCC包括7项研究 课程：细胞信号与新陈代谢、癌症进化机制、核受体、转录 和染色质生物学、乳腺癌、癌细胞和基因治疗、癌症预防和人口 科学和儿科癌症。重大投资加强了10个共享资源，其中 提供领先的技术。在先进的体内癌症模型中的一个新的共享资源进一步增强了我们的 能力。临床方案和数据管理核心已显著增强，并应计 临床试验的数量有所增加。种族和少数民族的应计利润突出。外展办公室 以及推动COE向社区传播新信息和服务的健康差距， 尤其是那些服务不足的人。培训和教育已通过CRCE纳入我们的计划 核心。在这次更新中，我们要求为我们的10项共享资源和其他扩大的活动增加资金 对我们的使命和目标很重要。

Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine OVERALL - PROJECT SUMMARY This is the 3nd CCSG competitive renewal application of the Dan L Duncan Comprehensive Cancer Center (DLDCCC) at Baylor College of Medicine (BCM) in Houston, Texas. Houston is the 4th largest city in the United States with a very diverse population and Harris County is one of the most rapidly growing in the country. The DLDCCC Catchment Area has expanded from the core of Harris county to include the 8 surrounding counties which comprise the Houston Metropolitan Statistical Area (MSA), representing a diverse population of more than 7 million individuals (this population is greater than 35 states). The DLDCCC is a matrix center with BCM as the lead partner with 4 hospital affiliates, Texas Children’s, the DeBakey Veterans Affairs Medical Center, Ben Taub Hospital, and the new Baylor St. Luke’s Medical Center as formal affiliates. The DLDCCC received NCI designation in 2007 and comprehensive designation in 2014 and through our evaluation and planning process and recommendations from our EAC and internal committees, we have since made significant progress strengthening our scientific programs. 53 new cancer faculty have been recruited to the DLDCCC which now has 192 Research members, 78 Clinical members and 18 Adjunct members. Our cancer-relevant peer reviewed research funding now exceeds $169 million, with more than $49 million ($34M direct) coming from the NCI. Several important scientific accomplishments have been made that have an impact in our Catchment Area and globally. The DLDCCC comprises 7 research programs: Cell Signaling and Metabolism, Mechanism of Cancer Evolution, Nuclear Receptor, Transcription and Chromatin Biology, Breast Cancer, Cancer Cell and Gene Therapy, Cancer Prevention and Population Science, and Pediatric Cancer. Significant investments have strengthened the 10 Shared Resources, which offer leading technologies. A new shared resource in Advanced In Vivo Cancer Models further enhances our capabilities. The Clinical Protocol and Data Management Core has been significantly enhanced and accruals to clinical trials have increased. Accrual of racial and ethnic minorities is outstanding. The Office of Outreach and Health Disparities which drives COE disseminates new information and services to the community, especially the underserved. Training and education have been integrated into our Programs through the CRCE core. In this renewal, we ask for increased funding for our 10 Shared Resources and other expanded activities important to our mission and goals.